<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40256">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01996423</url>
  </required_header>
  <id_info>
    <org_study_id>12-185</org_study_id>
    <secondary_id>1130615</secondary_id>
    <nct_id>NCT01996423</nct_id>
  </id_info>
  <brief_title>Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis</brief_title>
  <acronym>VIDATOPIC</acronym>
  <official_title>Impact of Vitamin D Supplementation on Clinical Severity and Immunologic Tolerance of Pediatric Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <authority>Chile: Comisión Nacional de Investigación Científica y Tecnológica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral vitamin D supplementation improves
      the clinical severity of atopic dermatitis in children. In addition, this study plans to
      evaluate the effects of vitamin D supplementation on several key aspects of the immune
      system of children with atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in SCORAD index</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Scoring Atopic Dermatitis (SCORAD) index after 6 weeks of vitamin D3 (VD3) supplementation or placebo in children with atopic dermatitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Th2 immunity</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Eosinophil blood counts, serum IgE, Th2 lymphocytes among stimulated PBMCs, serum CCL17, CCL22, and CCL27.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dendritic cell-mediated tolerance and regulatory T cells</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number and phenotype of blood dendritic cells and number of regulatory T cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of VD3 supplementation on immunity to Staphylococcus aureus</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum cathelicidin levels, S. aureus skin carriage, and specific IgE to staphylococcal enterotoxins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D receptor single nucleotide polymorphisms</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effect of VDR SNPs on the VD3 response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in epidermal protein expression</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gene expression of epidermal proteins by PCR obtained from lesional and non-lesional tape stripping samples.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events of atopic dermatitis patients with VD3 and placebo</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>Vitamin D3 supplementation</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atopic dermatitis diagnosed according to Hanifin and Rajka criteria

          -  Age 2 - 17 years

          -  SCORAD 10 - 103

        Exclusion Criteria:

          -  Active skin infection

          -  History of underlying illness causing immunosuppression within the past 2 years

          -  Immunosuppressors taken within the past month

          -  Parathyroid disease

          -  Sarcoidosis

          -  Acute or chronic renal disease

          -  Hyper or hypocalcemia

          -  Thyroid disease

          -  Osteomalacia or Paget's disease of bone

          -  Malabsorption

          -  Use of VD supplements (&gt; 400 IU daily) or fish oil supplements in the past month

          -  Treatment for known VD deficiency in the last 6 months

          -  Treatment with moderate or high potency topical corticosteroids, oral or topical
             antibiotics, oral antivirals, immune enhancers, or topical calcineurin inhibitors in
             the past 7 days

          -  Phototherapy in the past month

          -  Autoimmune disease or immunodeficiency

          -  Planned trip to sunny climate during the 6-week study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Borzutzky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine, Pontificia Universidad Católica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos A Camargo Jr., M.D., DrPH</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital, Harvard University, Boston, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristian Vera, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>School of Medicine, Pontificia Universidad Católica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorena Cifuentes, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>School of Medicine, Pontificia Universidad Católica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Silva, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>School of Medicine, Pontificia Universidad Católica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arturo Borzutzky, M.D.</last_name>
    <phone>56-2-23543753</phone>
    <email>arturobor@med.puc.cl</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Medicine, Pontificia Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catalina Le Roy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo Hoyos-Bachiloglu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristián Navarrete, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca Cristi, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolina Iturriaga, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>November 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>vitamin D</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
